The Conatus Pharmaceuticals’ (CNAT) “Buy” Rating Reiterate at the JMP Securities

The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.03.

Advertisements
The Conatus Pharmaceuticals’ (CNAT) “Buy” Rating Reiterate at the JMP Securities

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s